Skip Navigation



Annals of Oncology Advance Access published online on May 12, 2005
Annals of Oncology, doi:10.1093/annonc/mdi245
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/8/1237    most recent
mdi245v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barranger, E.
Right arrow Articles by Darai, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barranger, E.
Right arrow Articles by Darai, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received November 5, 2004
Revised February 22, 2005
Accepted March 3, 2005

Original article

Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease

E. Barranger 1*, C. Coutant 1, A. Cortez 2, S. Uzan 1, and E. Darai 1

1 Department of Gynecologic and Breast Tumor,, Assistance Publique des Hôpitaux de Paris, 4 rue de la Chine, 75020 Paris, France
2 Department of Pathology, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, 4 rue de la Chine, 75020 Paris, France

* To whom correspondence should be addressed.
E. Barranger, E-mail: emmanuel.barranger{at}tnn.ap-hop-paris.fr


  Abstract

Background: Sentinel lymph node (SN) biopsy based on dual labeling with blue dye and radiocolloid can reliably determine lymph node status in early-stage cervical cancer, but few data are available on its accuracy in more advanced disease. We examined the influence of tumor stage on the accuracy of SN biopsy in patients with cervical cancer.

Methods: Between July 2001 and June 2004, 33 patients (mean age 52 years) with early-stage or locally advanced cervical cancer underwent laparoscopic SN biopsy based on dual labeling with patent blue and radiocolloid. Patients with early-stage cervical cancer (stages IA and IB1, 23 patients) underwent complete laparoscopic pelvic lymphadenectomy after the SN procedure. Patients with locally advanced cervical cancer (stage IB2, IIA or IIB, 10 patients) underwent laparoscopic pelvic and para-aortic lymphadenectomy after SN biopsy and prior neoadjuvant concomitant chemoradiotherapy. The SN identification rates and false-negative rates of patients with early-stage and locally advanced disease were compared.

Results: The mean numbers of SNs identified per patient with early-stage and locally advanced cervical cancer were 2.3 (range 0-4) and 1.9 (range 0-4), respectively. SNs were identified in 86.9% (20/23) of patients with early-stage disease and in 80% (8/10) of patients with locally advanced disease. When analyzed according to the side of dissection, the identification rate was lower, especially in the patients with locally advanced disease (55% compared with 67.4%). The false-negative rate per patient was zero in early-stage disease and 20% (1/5) in locally advanced disease (no significant difference). When the side of dissection was taken into account, the false-negative rate improved to 42.9% (3/7) in patients with locally advanced disease and remained at zero in early-stage disease (P=0.038). Isolated blue dye was taken up in 53.3% of SNs in patients with locally advanced disease, compared with only 6.4% in patients with early-stage disease.

Conclusions: This study suggests that the SN biopsy technique with dual labeling is less accurate in locally advanced cervical cancer than in early-stage cervical cancer.

Keywords: cervical cancer; combined detection; laparoscopy; locally advanced disease; sentinel node biopsy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
A.-S. Bats, V. Lavoue, R. Rouzier, C. Coutant, K. Kerrou, and E. Darai
Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer
Ann. Surg. Oncol., August 1, 2008; 15(8): 2173 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. T. Gien and A. Covens
Quality Control in Sentinel Lymph Node Biopsy in Cervical Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2930 - 2931.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
V. Lavoue, A.-S. Bats, R. Rouzier, C. Coutant, E. Barranger, and E. Darai
Sentinel lymph node procedure followed by laparoscopic pelvic and paraaortic lymphadenectomy in women with IB2-II cervical cancer
Ann. Surg. Oncol., September 1, 2007; 14(9): 2654 - 2661.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Coutant, E Barranger, A Cortez, D Dabit, S Uzan, J. Bernaudin, and E Darai
Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer
Ann. Onc., September 1, 2007; 18(9): 1513 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. J. Lejeune
What is the impact of sentinel node biopsy in the management of cancer?
Ann. Onc., August 1, 2005; 16(8): 1217 - 1218.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.